AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9421775 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of cefuroxime (3 g or 1.5 g)
Number of subjects: 60
Study 9421775 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of vancomycin (1.5 g)
Number of subjects: 60
Study 9421775 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day course of cefuroxime
Number of subjects: 60
Study 9421775 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional dose during cardiopulmonary bypass of cefuroxime
Number of subjects: 60
Study 9421775 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of cefuroxime
Number of subjects: 60
Study 9421775 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of vancomycin
Number of subjects: 60
Study 8335738 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluocinolone acetonide ointment (0.025%) diluted by area of application
Number of subjects: 20
Study 8335738 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluocinolone acetonide ointment (0.025%) diluted by volume (1:1 and 1:3)
Number of subjects: 20
Study 8335738 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro method measuring fluocinolone release from diluted ointments
Number of subjects: 20
Study 3117998 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg/d lipid for 5 days (group 1)
Number of subjects: 21
Study 3117998 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg/d increased to 2.0 g/kg/d over 5 days (group 2)
Number of subjects: 21
Study 3117998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion at 0.5 to 2.0 g/kg/d
Number of subjects: 21
Study 3117998 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 21
Study 3117998 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatically determined triglycerides
Number of subjects: 21
Study 30591165 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental advancement (IA)
Number of subjects: 42
Study 30591165 — intervention group
Group type: COMPARATOR
Intervention: Maximum advancement (MA)
Number of subjects: 42
Study 29936091 — intervention group
Group type: EXPERIMENTAL
Intervention: Onnikka system (web-based HBCSS)
Number of subjects: 43
Study 26785406 — intervention group
Group type: EXPERIMENTAL
Intervention: HeLP‐her self‐management lifestyle intervention (1 group session, monthly SMS text messages, 1 phone coaching session, program manual)
Number of subjects: 649
Study 26785406 — intervention group
Group type: COMPARATOR
Intervention: General women's health education session (control group)
Number of subjects: 649
Study 26785406 — intervention group
Group type: EXPERIMENTAL
Intervention: HeLP‐her self‐management lifestyle intervention
Number of subjects: 649
Study 25197804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetazolamide (10 mg/kg)
Number of subjects: 12
Study 25197804 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin (100 mg)
Number of subjects: 12
Study 22252827 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 450 mg daily
Number of subjects: 1
Study 22252827 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg daily
Number of subjects: 1
Study 19210274 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdialytic weight gain (IDWG)
Number of subjects: 97
Study 17179509 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition (SGA categorized)
Number of subjects: 56
Study 17179509 — intervention group
Group type: COMPARATOR
Intervention: Normal nutritional status (SGA categorized)
Number of subjects: 56
Study 17179509 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition (SGA)
Number of subjects: 56
Study 17179509 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Risk Index (NRI)
Number of subjects: 56
Study 17179509 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin level
Number of subjects: 56
Study 17179509 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie intake
Number of subjects: 56
Study 17179509 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA (multivariate analysis)
Number of subjects: 56
Study 17179509 — intervention group
Group type: COMPARATOR
Intervention: Normal nutrition
Number of subjects: 56
Study 17179509 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition
Number of subjects: 56
Study 15173147 — intervention group
Group type: EXPERIMENTAL
Intervention: Progresa intervention group (n = 373)
Number of subjects: 650
Study 15173147 — intervention group
Group type: COMPARATOR
Intervention: Crossover intervention group (n = 277)
Number of subjects: 650
Study 11228084 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg twice daily
Number of subjects: 56
Study 11228084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 9929322 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Term Composition (ATC) algorithm
Number of subjects: 1000
Study 9929322 — intervention group
Group type: COMPARATOR
Intervention: Non-compositional mappings (without ATC)
Number of subjects: 1000
Study 7886417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraurethral capsaicin (10(‐5) M)
Number of subjects: 20
Study 7886417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal papaverine hydrochloride (8 mg) plus intraurethral capsaicin (10(‐5) M)
Number of subjects: 20
Study 7886417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal papaverine hydrochloride (8 mg) plus intraurethral saline infusion
Number of subjects: 20
Study 7886417 — intervention group
Group type: COMPARATOR
Intervention: Intraurethral saline solution
Number of subjects: 20
Study 3279748 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg/d)
Number of subjects: 50
Study 3279748 — intervention group
Group type: COMPARATOR
Intervention: Ascorbate (Control)
Number of subjects: 50
Study 30025466 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival processing effect in isolated condition
Number of subjects: 0
Study 30025466 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition rates for isolated condition
Number of subjects: 0
Study 30025466 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived isolation in grasslands scenarios
Number of subjects: 0
Study 27986972 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU weekly for 12 weeks)
Number of subjects: 39
Study 27986972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 25651782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 15 mg BID
Number of subjects: 0
Study 25651782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25651782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (0.5 mg, 3 mg, 10 mg)
Number of subjects: 0
Study 25651782 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic remission (Mayo endoscopy score of 0)
Number of subjects: 0
Study 23991625 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive PCI
Number of subjects: 465
Study 23991625 — intervention group
Group type: COMPARATOR
Intervention: No preventive PCI (infarct-artery-only PCI)
Number of subjects: 465
Study 21903531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride in combination with sodium fluoride
Number of subjects: 12
Study 21903531 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Number of subjects: 12
Study 21903531 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate and sodium fluoride
Number of subjects: 12
Study 21903531 — intervention group
Group type: COMPARATOR
Intervention: Control (fluoride toothpaste and rinsing with water)
Number of subjects: 12
Study 21903531 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium monofluorophosphate
Number of subjects: 12
Study 19036672 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (TGC)
Number of subjects: 358
Study 19036672 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (LEV)
Number of subjects: 358
Study 16310895 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 1500 units
Number of subjects: 110
Study 16310895 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 15 mg
Number of subjects: 110
Study 16310895 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Heparin and Hydrocortisone
Number of subjects: 110
Study 14600553 — intervention group
Group type: EXPERIMENTAL
Intervention: INT (maintained training intensity but reduced duration)
Number of subjects: 22
Study 14600553 — intervention group
Group type: EXPERIMENTAL
Intervention: DUR (maintained training duration but reduced exercise intensity)
Number of subjects: 22
Study 14600553 — intervention group
Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 22
Study 14600553 — intervention group
Group type: COMPARATOR
Intervention: CON (continued weekly training)
Number of subjects: 22
Study 10724078 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS 1 (5 Hz)
Number of subjects: 70
Study 10724078 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS 2 (100 Hz)
Number of subjects: 70
Study 10724078 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS 3 (200 Hz)
Number of subjects: 70
Study 10724078 — intervention group
Group type: EXPERIMENTAL
Intervention: IFT 1 (5 Hz)
Number of subjects: 70
Study 10724078 — intervention group
Group type: EXPERIMENTAL
Intervention: IFT 2 (100 Hz)
Number of subjects: 70
Study 10724078 — intervention group
Group type: EXPERIMENTAL
Intervention: IFT 3 (200 Hz)
Number of subjects: 70
Study 10724078 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 9366278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 312
Study 9366278 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 312
Study 1539506 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (streptokinase)
Number of subjects: 50
Study 1539506 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (rt-PA)
Number of subjects: 50
Study 1539506 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy preceded by acetylsalicylic acid
Number of subjects: 50
Study 1539506 — intervention group
Group type: COMPARATOR
Intervention: No thrombolytic therapy
Number of subjects: 50
Study 1539506 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfused patients
Number of subjects: 50
Study 1539506 — intervention group
Group type: COMPARATOR
Intervention: Occluded patients
Number of subjects: 50
Study 3894707 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2-g dose of metronidazole
Number of subjects: 82
Study 3894707 — intervention group
Group type: COMPARATOR
Intervention: Seven-day course of 500 mg metronidazole given twice daily
Number of subjects: 82
Study 31323378 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline anxiety or depression
Number of subjects: 1159
Study 31323378 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-GI symptoms
Number of subjects: 1159
Study 31323378 — intervention group
Group type: COMPARATOR
Intervention: Anxiety or depression
Number of subjects: 1159
Study 30015668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Number of subjects: 214
Study 30015668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 26768925 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 90
Study 26768925 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 90
Study 25302763 — intervention group
Group type: EXPERIMENTAL
Intervention: MBCT‐SH
Number of subjects: 80
Study 25302763 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 80
Study 22918524 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 82
Study 22918524 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of processing training
Number of subjects: 82
Study 22918524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 82
Study 20194027 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction
Number of subjects: 0
Study 20194027 — intervention group
Group type: COMPARATOR
Intervention: Non-suction
Number of subjects: 0
Study 18084150 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 0
Study 18084150 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve repair or replacement
Number of subjects: 0
Study 18084150 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery of left ventricular shape and volume restoration
Number of subjects: 0
Study 18084150 — intervention group
Group type: COMPARATOR
Intervention: Ongoing prospective randomized studies (Surgical Treatment for Ischemic Heart Disease trial, Heart Failure Revascularization trial, PET and Recovery Following Revascularization-2 trial)
Number of subjects: 0
Study 16045667 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular block (single injection)
Number of subjects: 80
Study 16045667 — intervention group
Group type: COMPARATOR
Intervention: Axillary block (multiple injections)
Number of subjects: 80
Study 12225436 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 135
Study 12225436 — intervention group
Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATGAM)
Number of subjects: 135
Study 10223773 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once a day for 5 days
Number of subjects: 10
Study 10223773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7872274 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine (1 g daily)
Number of subjects: 322
Study 7872274 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine (2 g daily)
Number of subjects: 322
Study 2152843 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Hospital Support Program
Number of subjects: 191
Study 2152843 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 191
Study 680588 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestricted sodium intake
Number of subjects: 201
Study 680588 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial removal of ascites (limitation of diuresis)
Number of subjects: 201
Study 680588 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete diuresis
Number of subjects: 201
Study 680588 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet
Number of subjects: 201
Study 31733140 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg once daily)
Number of subjects: 4745
Study 28081288 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (6 mm)
Number of subjects: 101
Study 28081288 — intervention group
Group type: COMPARATOR
Intervention: Long implants (11‐15 mm)
Number of subjects: 101
Study 28081288 — intervention group
Group type: COMPARATOR
Intervention: Long implants (11‐15 mm) with sinus grafting
Number of subjects: 101
Study 28081288 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (6 mm) with sinus grafting
Number of subjects: 101
Study 28081288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study 25596939 — intervention group
Group type: EXPERIMENTAL
Intervention: Evicel™ (biologic glue)
Number of subjects: 165
Study 25596939 — intervention group
Group type: EXPERIMENTAL
Intervention: Over suture of the stapler line
Number of subjects: 165
Study 25596939 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 165
Study 23414585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganitumab (12 mg/kg bodyweight) + Fulvestrant (500 mg on day 1, then 250 mg on days 15, 29, and every 28 days)
Number of subjects: 156
Study 23414585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganitumab (12 mg/kg bodyweight) + Exemestane (25 mg once daily)
Number of subjects: 156
Study 23414585 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Fulvestrant (500 mg on day 1, then 250 mg on days 15, 29, and every 28 days)
Number of subjects: 156
Study 23414585 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Exemestane (25 mg once daily)
Number of subjects: 156
Study 23414585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganitumab (12 mg/kg bodyweight)
Number of subjects: 156
Study 23414585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 19858112 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct feedback (COR)
Number of subjects: 5
Study 19858112 — intervention group
Group type: COMPARATOR
Intervention: Non-contingent feedback (FAL)
Number of subjects: 5
Study 19118617 — intervention group
Group type: EXPERIMENTAL
Intervention: Shi-Bi-Lin (SBL) capsules
Number of subjects: 126
Study 19118617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 16500713 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (30 mg)
Number of subjects: 18
Study 16500713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 14693608 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric needle acupuncture over 15 min at analgesic points of the leg (n = 8)
Number of subjects: 16
Study 14693608 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (n = 8)
Number of subjects: 16
Study 11020090 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation-based stress reduction program (weekly meditation group lasting 1.5 hours for 7 weeks plus home meditation practice)
Number of subjects: 90
Study 11020090 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 90
Study 9362436 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium nitrate (40 mg administered as a subcutaneous injection once daily for 2 weeks, followed by 2 weeks off treatment, recycled monthly)
Number of subjects: 0
Study 7510194 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF administration
Number of subjects: 0
Study 3511159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 25
Study 3511159 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 25
Study 3174261 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotonous stimulation (sequence of tones)
Number of subjects: 60
Study 3174261 — intervention group
Group type: COMPARATOR
Intervention: No tones (quiet room)
Number of subjects: 60
Study 31506918 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle tip tracking
Number of subjects: 25
Study 31506918 — intervention group
Group type: COMPARATOR
Intervention: No needle tip tracking (control)
Number of subjects: 25
Study 30991829 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-Needle Aspiration (FNA)
Number of subjects: 24
Study 30991829 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 24
Study 27619354 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including education, guideline development, elimination of recurring laboratory orders, unbundling of laboratory panels, redesign of the daily progress note.
Number of subjects: 5392
Study 27619354 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 5392
Study 26276164 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) - 150 ml ropivacaine 0.2 % with epinephrine intra‐operatively
Number of subjects: 61
Study 26276164 — intervention group
Group type: COMPARATOR
Intervention: Interscalene brachial plexus catheter (ISC) - ropivacaine 0.75 %, 7 ml bolus followed by 48‐h 5 ml/h infusion
Number of subjects: 61
Study 26276164 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 61
Study 26276164 — intervention group
Group type: COMPARATOR
Intervention: Interscalene brachial plexus catheter (ISC)
Number of subjects: 61
Study 23505176 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 500 calorie liquid meals every 4 hours
Number of subjects: 8
Study 23505176 — intervention group
Group type: COMPARATOR
Intervention: Six 250 calorie liquid meals every 2 hours
Number of subjects: 8
Study 21143256 — intervention group
Group type: EXPERIMENTAL
Intervention: Predefined pharmacist intervention focusing on correct medication use, medication adherence, and healthy lifestyle promotion
Number of subjects: 288
Study 21143256 — intervention group
Group type: EXPERIMENTAL
Intervention: Predefined pharmacist intervention with sustained pharmacotherapy changes
Number of subjects: 288
Study 21143256 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving usual pharmacist care
Number of subjects: 288
Study 21143256 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group receiving pharmacist intervention
Number of subjects: 288
Study 19941542 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive education programme for 1 hour and educational booklet
Number of subjects: 90
Study 19941542 — intervention group
Group type: COMPARATOR
Intervention: Control group (received the same intervention separately after post-test)
Number of subjects: 90
Study 17009533 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate + levofloxacin (first 4 weeks), Prostate only (next 4 weeks)
Number of subjects: 160
Study 17009533 — intervention group
Group type: COMPARATOR
Intervention: Placebo + levofloxacin (first 4 weeks), Placebo only (next 4 weeks)
Number of subjects: 160
Study 15598919 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) or combined cardiac resynchronization therapy and defibrillator (CRT-D)
Number of subjects: 2146
Study 15598919 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 2146
Study 15598919 — intervention group
Group type: EXPERIMENTAL
Intervention: All trials combined (ICD therapy)
Number of subjects: 2146
Study 11307470 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide and eugenol sealer (Fill Canal)
Number of subjects: 99
Study 11307470 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer sealer (Ketac‐Endo)
Number of subjects: 99
Study 11307470 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoxy resin sealer (AH Plus)
Number of subjects: 99
Study 10021718 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/kg porcine surfactant (Group A)
Number of subjects: 165
Study 10021718 — intervention group
Group type: COMPARATOR
Intervention: 100 mg/kg porcine surfactant (Group B)
Number of subjects: 165